Next Article in Journal
Structural Diversity of the Microbial Surfactin Derivatives from Selective Esterification Approach
Previous Article in Journal
Non-Classical Gluconeogenesis-Dependent Glucose Metabolism in Rhipicephalus microplus Embryonic Cell Line BME26
Article

Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation

1
Department of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan
2
Department of Urology, Akita University School of Medicine, Akita 010-8543, Japan
3
Center for Kidney Disease and Transplantation, Akita University Hospital, Akita 010-8543, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Int. J. Mol. Sci. 2015, 16(1), 1840-1854; https://doi.org/10.3390/ijms16011840
Received: 3 November 2014 / Accepted: 6 January 2015 / Published: 14 January 2015
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
While CYP3A5 polymorphisms are used to predict the initial dosage of tacrolimus therapy, the predictive capability of genetic information for dosing at early stage post-renal transplantation is unknown. We investigated the influence of polymorphisms over time. An initial oral dose of modified-release once-daily tacrolimus formulation (0.20 mg/kg) was administered to 50 Japanese renal transplant patients every 24 h. Stepwise multiple linear regression analysis for tacrolimus dosing was performed each week to determine the effect of patient clinical characteristics. The dose-adjusted trough concentration was approximately 70% higher for patients with the CYP3A5*3/*3 than patients with the CYP3A5*1 allele before the second pre-transplantation tacrolimus dose (0.97 (0.78–1.17) vs. 0.59 (0.45–0.87) ng/mL/mg; p < 0.001). The contribution of genetic factors (CYP3A5*1 or *3) for tacrolimus dosing showed increased variation from Day 14 to Day 28 after transplantation: 7.2%, 18.4% and 19.5% on Days 14, 21 and 28, respectively. The influence of CYP3A5 polymorphisms on the tacrolimus maintenance dosage became evident after Day 14 post-transplantation, although the tacrolimus dosage was determined based only on patient body weight for the first three days after surgery. Tacrolimus dosage starting with the initial administration should be individualized using the CYP3A5 genotype information. View Full-Text
Keywords: CYP3A5; tacrolimus; once-daily; dose variability; renal transplantation CYP3A5; tacrolimus; once-daily; dose variability; renal transplantation
Show Figures

Figure 1

MDPI and ACS Style

Niioka, T.; Kagaya, H.; Saito, M.; Inoue, T.; Numakura, K.; Habuchi, T.; Satoh, S.; Miura, M. Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation. Int. J. Mol. Sci. 2015, 16, 1840-1854. https://doi.org/10.3390/ijms16011840

AMA Style

Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Habuchi T, Satoh S, Miura M. Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation. International Journal of Molecular Sciences. 2015; 16(1):1840-1854. https://doi.org/10.3390/ijms16011840

Chicago/Turabian Style

Niioka, Takenori, Hideaki Kagaya, Mitsuru Saito, Takamitsu Inoue, Kazuyuki Numakura, Tomonori Habuchi, Shigeru Satoh, and Masatomo Miura. 2015. "Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation" International Journal of Molecular Sciences 16, no. 1: 1840-1854. https://doi.org/10.3390/ijms16011840

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop